

8780 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

issues of the FDA Drug Bulletin will include progress reports on the Agency's drug reaction surveillance program.

¹National Academy of Sciences: Report of the International Conference on Adverse Reactions Reporting Systems, Washington, D.C., 1971, page 1.

DRUG EXPERIENCE REPORT <i>(IN CONFIDENCE)</i>			Form Approved OMB No. XXXXXXX	
PATIENT INITIALS <i>(Optional)</i>			DATE OF REACTION ONSET	
SUSPECTED REACTION(S)				
SUSPECTED DRUG(S); TRADE/GENERIC NAME <i>(Manufacturer's name, if possible)</i>				
DISORDER OR REASON FOR USE OF DRUG(S) <i>(Optional)</i>	ROUTE	TOTAL DAILY DOSE	DATES OF ADMINISTRATION	
OTHER DRUGS TAKEN CONCOMITANTLY				
COMMENTS <i>(Optional)</i>				
PHYSICIAN'S NAME, ADDRESS, AND ZIP CODE				

FD PROPOSED FORM